ABCL
Abcellera Biologics
$5.25
−$0.06 (−1.13%)Jul 27, 2026
Key metrics
The numbers that frame ABCL today
- Market cap
- $1.60B
- P/E (TTM)
- -11.1
- EV / FCF
- -8.6
- Gross margin
- 100%
- EV / Sales
- 20.6
- ROIC
- -14.5%
- Div yield
- 0%
- Debt / equity
- 0.1
- 52wk Low
- $2.75
- 52wk High
- $8.44
Growth
Revenue and earnings trend for ABCL
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about ABCL
Is Abcellera Biologics a good buy?
Hold. Abcellera Biologics has excellent momentum, but weak quality makes the setup mixed. Growth looks weak. That could put pressure on the long-term business case. We think Abcellera Biologics is selling at a very high price.
What is the market capitalization of ABCL?
Abcellera Biologics's market capitalization is $1.60B.
What is the P/E ratio for ABCL stock?
Abcellera Biologics's current P/E ratio is -11.1.
What is the 52-week high for ABCL stock?
The 52-week high for Abcellera Biologics is $8.44. The current close of $5.25 is 37.8% below that high.
What is the 52-week low for ABCL stock?
The 52-week low for Abcellera Biologics is $2.75. The current close of $5.25 is 91.3% above that low.
Does ABCL stock pay dividends?
Abcellera Biologics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for ABCL?
Abcellera Biologics's Debt / Equity ratio is 0.14.